x-c-bleeding is the first of x-cardiac’s products to receive market authorization. A second product, x-c-renal-injury, is under development. Both employ AI-based algorithms to collate and evaluate data from various monitoring instruments, allowing potential critical complications, such as post-operative bleeding or acute renal failure, to be predicted. The earlier these can be recognized, the better the chances of successful treatment. The software was developed by Prof. Alexander Meyer, physician and computer scientist at the German Heart Center Berlin (DHZB), and trained using the anonymized data of more than 50,000 patients at the DHZB.
The DHZB, the Berlin Institute of Health (BIH) and the Charité – Universitätsmedizin Berlin have supported the start-up. The seed financing was successfully closed in April this year. Ascenion GmbH, technology transfer partner of Charité and BIH, holds equity in x-cardiac.
Further information: x-cardiac’s press release (available in German only)